Quantcast

Latest H5N1 clinical trials Stories

2010-02-08 01:00:00

ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals (Madrid: ROVI) to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain. This decision is due to the companies' inability to agree on acceptable terms of the proposed collaboration and to obtain the necessary...

2010-02-04 12:13:03

Global partnership enabled testing in Mali, West Africa, where malaria threat is high A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients "” young children "” against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa. In a new...

2010-01-28 19:47:41

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed the vaccine because there is no vaccine or treatment for chikungunya virus infection. Details...

2010-01-13 08:00:00

VIENNA, Austria, January 13 /PRNewswire/ -- - By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010 - The Positive Results Obtained in the Previous Clinical Phase I Study will be Published in the Renowned "Journal of Infectious Diseases" on 15 January 2010 AVIR Green Hills Biotechnology, the innovative...

2009-12-28 07:00:00

BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China. No vaccine or antiviral...

25fee368bc94161000aefac4fdfc84f71
2009-12-26 07:05:00

Accelerated approval process used in vaccine approval The U.S. Food and Drug Administration this week approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B. People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Annual vaccination remains the best protection from influenza, particularly for people 65 and...

2009-12-21 15:13:04

One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal. Initial reports of 2009 influenza A(H1N1) infection in many countries have largely involved children, especially those attending school. Reports have also indicated high hospitalization rates of children younger than 5...

2009-12-15 08:00:00

LYON, France and SWIFTWATER, Pa., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is expanding its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the United States. The trial started in the United Kingdom earlier this year. The incidence of CDI has increased significantly in recent years in both North America and Europe. CDI-related treatments in these two regions of the...

7c002da4103729c4eebdccee1a004240
2009-12-04 10:35:00

The European Medicines Agency announced that young children who are receiving GlaxoSmithKline's H1N1 vaccine may contract a fever after the second injection. In a statement was released Friday, and the European drug controller added that statistics pulled from GlaxoSmithKline PLC indicated a large amount of children from six months to 3 years contracted a fever after the second dose of the vaccine. Other side effects reported included muscle discomfort, sleepiness, and irritability. The...

2009-12-02 07:05:00

ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries. In Stage A of this...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.